Antibody-drug conjugate · Cytotoxic, directed at CD30 (TNFRSF8) · developed by Seattle Genetics
ApprovedFDA, Aug 2011
What is Brentuximab Vedotin?
Brentuximab vedotin is an antibody-drug conjugate in which a chimeric IgG1 antibody binds CD30, and the microtubule-disrupting agent MMAE is attached through a cleavable linker. After binding and internalization by CD30-expressing cells, MMAE is released and disrupts microtubules, causing cell cycle arrest and apoptosis. It is studied in diffuse large B-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Adcetris, CAC10-VCMMAE, SGN-35
Drug type
Antibody-drug conjugate
Targets
CD30 (TNFRSF8)
Mechanism
Cytotoxic, directed at CD30 (TNFRSF8)
Pathways
CD30-CD30L signaling affecting cell survival and proliferation, microtubule disruption, cell cycle arrest and apoptosis, antibody-dependent cellular phagocytosis
From the indications section of the FDA label (version of Nov 11, 2025). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.